Comparison of clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without anti-connective tissue antibodies: an 18-month cohort follow-up - Scorecard - MDSpire
Advertisement
Comparison of clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without anti-connective tissue antibodies: an 18-month cohort follow-up
Clinical Scorecard: Evaluation of Clinical and Laboratory Features in Neuromyelitis Optica Spectrum Disorder with and without Anti-Connective Tissue Antibodies: Findings from an 18-Month Cohort Study
At a Glance
Category
Detail
Condition
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Key Mechanisms
Pathogenic autoantibodies targeting aquaporin-4 (AQP4) proteins lead to inflammatory responses and CNS damage.
Target Population
Patients with AQP4-IgG-positive NMOSD
Care Setting
Neurology department in a hospital
Key Highlights
52.7% of patients were positive for anti-connective tissue antibodies (CTD abs+).
CTD abs+ patients exhibited higher lymphocyte counts and CSF white blood cell counts.
Higher Expanded Disability Status Scale scores were noted in CTD abs+ patients at first relapse.
CTD abs positivity was associated with a higher annualized relapse rate.
No significant differences in lesion distribution or length of spinal cord segments were observed between groups.
Guideline-Based Recommendations
Diagnosis
Diagnosis of NMOSD should follow the 2015 International Panel for NMO diagnostic criteria.
Management
Consider the presence of CTD abs when evaluating disease severity and relapse rates.
Monitoring & Follow-up
Monitor lymphocyte counts, CSF white blood cell counts, and EDSS scores during follow-up.
Risks
Patients with CTD abs+ may experience a higher annualized relapse rate.
Patient & Prescribing Data
205 patients with AQP4-IgG-positive NMOSD
CTD abs+ patients may require closer monitoring due to higher disease activity.
Clinical Best Practices
Assess for CTD abs in patients diagnosed with NMOSD to evaluate inflammatory profiles.
Utilize EDSS scores for assessing disability and disease progression.
